Skip to main content

Newsroom

Please see below links to the most recent news and events for IDEAYA.

 

Media Contacts News Alerts LinkedIn

 
Latest Press
Mar 12, 2024

­Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial...

Mar 4, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Feb 20, 2024

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study...

All News

Featured Stories
Stay up-to-date with us
GET EMAIL ALERTS
* Required Fields
Close Menu